Month: May 2013

Nice’s Scientific Credibility Compromised By Recent Amendment To Appraisal Methods

Toronto, ON, Canada – The National Institute for Health and Care Excellence (NICE) is highly regarded for the rigorous methods it adopts for the economic appraisal of health care technologies. A recent amendment to these appraisal methods, however, raises a number

Posted in Commentary, Value in Health Tagged with: , , , ,

Pharmacoeconomic Guidelines Unclear On Dealing With Patient Differences

Maastricht, The Netherlands – Acknowledging patient heterogeneity in economic evaluations and subsequent reimbursement decisions may lead to more effective and/or efficient health care. Despite this potential gain, patient heterogeneity is still frequently neglected in economic evaluations.

Posted in Systematic Reviews, Value in Health Tagged with: , , , ,

Evaluating Diagnostic Strategies Involving Multiple Tests

Leicester, UK – It is essential that the relationships between diagnostic tests are understood in order to ensure the most effective diagnoses of diseases, as they rarely perform independently. To date, both clinical and economic evaluations of combinations of diagnostic tests

Posted in Comparative Effectiveness Research / Health Technology Assessment, Value in Health Tagged with: , , , , ,

A Value Proposition For Specialty Medications

Newark, DE, USA – Hospitals, physicians, payers and patients face economic and ethical decisions about the use of biotechnology drugs, commonly called specialty medications. Medicare, physician guidelines and consensus statements currently include specialty drugs without an assessment of value, resulting in

Posted in Policy Perspectives, Value in Health Tagged with: , , , ,

Illustrating Potential Efficiency Gains From Using Cost-Effectiveness Evidence To Reallocate Medicare Expenditures For Medical Technology

Boston, MA, USA – Researchers from the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center have illustrated potential health gains from using cost-effectiveness evidence to inform Medicare resource allocation for medical technology.  Focusing on interventions

Posted in Health Policy Analyses, Value in Health Tagged with: , , ,

Patients Willing To Pay More For Avoiding Symptoms Of GERD

Hamilton, ON, Canada – Gastroesophageal reflux disease (GERD) affects about 25% of the population in Western countries. Patients suffer symptoms at least monthly and five percent have daily heartburn.

Posted in Preference-Based Assessments, Value in Health Tagged with: , , , ,